TORONTO, June 6, 2023 /CNW/ - Intellipharmaceutics International Inc. (OTCQB: IPCIF) (TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the year ended November 30, 2022 and for the first quarter ended February 28, 2023. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
Read more at newswire.caIntellipharmaceutics Announces Fiscal Year 2022 and First Quarter 2023 Results
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.
